Literature DB >> 24525513

SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis.

Theo J M Hulsebos1, Susan Kenter, Ulrike Siebers-Renelt, Volkmar Hans, Pieter Wesseling, Uta Flucke.   

Abstract

Germline SMARCB1 mutations predispose in schwannomatosis patients to the development of multiple benign schwannomas and, in some cases, meningiomas. Here, we report on a 34-year-old female patient who developed multiple schwannomas at various locations and in addition a leiomyoma of the cervix uteri. She carried a c.362+1G>A mutation that inactivates the donor splice site of exon 3. This mutation caused the schwannomatosis phenotype in this patient and was also demonstrated to be present in her affected mother. The leiomyoma displayed the genetic features that are characteristic for germline SMARCB1 mutation-associated tumors. The mutant allele retained in the tumor, whereas the wild-type allele was lost by loss of heterozygosity. Furthermore, the loss of heterozygosity involved net loss of chromosome 22. An NF2 mutation was not found. However, quantitative polymerase chain reaction suggested that both NF2 copies were lost in the tumor. Immunostaining with a SMARCB1 antibody revealed the mosaic expression pattern that is typical for schwannomatosis-associated tumors. To our knowledge, this is the first reported case of leiomyoma associated with a germline SMARCB1 mutation. As such, it widens the spectrum of benign tumors associated with a germline SMARCB1 mutation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525513     DOI: 10.1097/PAS.0000000000000110

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

Review 1.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

2.  Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.

Authors:  Judith A Eelloo; Miriam J Smith; Naomi L Bowers; John Ealing; Paul Hulse; James P Wylie; Patrick Shenjere; Noel W Clarke; Calvin Soh; Richard W Whitehouse; Mark Jones; Christopher Duff; Anthony Freemont; D Gareth Evans
Journal:  Fam Cancer       Date:  2019-10       Impact factor: 2.375

3.  Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.

Authors:  Miika Mehine; Eevi Kaasinen; Hanna-Riikka Heinonen; Netta Mäkinen; Kati Kämpjärvi; Nanna Sarvilinna; Mervi Aavikko; Anna Vähärautio; Annukka Pasanen; Ralf Bützow; Oskari Heikinheimo; Jari Sjöberg; Esa Pitkänen; Pia Vahteristo; Lauri A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

4.  SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.

Authors:  Abbas Agaimy; Michael Koch; Michael Lell; Sabine Semrau; Wojciech Dudek; David L Wachter; Antje Knöll; Heinrich Iro; Florian Haller; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

Review 5.  The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.

Authors:  Hildegard Kehrer-Sawatzki; Said Farschtschi; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2016-12-05       Impact factor: 4.132

Review 6.  Oncogenic roles of SMARCB1/INI1 and its deficient tumors.

Authors:  Kenichi Kohashi; Yoshinao Oda
Journal:  Cancer Sci       Date:  2017-04-12       Impact factor: 6.716

7.  Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.

Authors:  M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut
Journal:  Fam Cancer       Date:  2021-02-03       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.